Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Archives of Internal Medicine

• Publication date

  2004-11-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.164.21.2371PMID 15557418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.

  2002cited by this paper
• Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study

  2002cited by this paper
• Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C.

  2001cited by this paper
• Extrahepatic manifestations of chronic viral hepatitis

  2001cited by this paper
• Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations.

  2001cited by this paper
• Radioiodine uptake and thyroid scintiscanning.

  2001cited by this paper
• Ribavirin - current status of a broad spectrum antiviral agent

  2001cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.

  2000cited by this paper
• Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin.

  2000cited by this paper
• Update on the management of hyperthyroidism and hypothyroidism.

  2000cited by this paper
• American Thyroid Association guidelines for detection of thyroid dysfunction.

  2000cited by this paper
• The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

  1999cited by this paper
• Extrahepatic manifestations of HCV infection: facts and controversies.

  1999cited by this paper
• HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C.

  1999cited by this paper
• Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics

  1999cited by this paper
• Low‐titre auto‐antibodies predict autoimmune disease during interferon‐α treatment of chronic hepatitis C

  1999cited by this paper
• Interferon-alpha-induced thyroid dysfunction in patients with chronic active hepatitis C: a transient, reversible and self-limited dysfunction.

  1998cited by this paper
• Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

  1998cited by this paper
• Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients.

  1998cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Incidence and characteristics of thyroid dysfunction following interferon therapy in patients with chronic hepatitis C.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• Hepatitis C: global prevalence.

  1997cited by this paper
• Extrahepatic manifestations of chronic viral hepatitis.

  1997cited by this paper
• Interferon-α Induced Thyroid Dysfunction: Three Clinical Presentations and a Review of the Literature

  1997cited by this paper
• Interferon-Associated Thyroid Dysfunction in Anti-D-Related Chronic Hepatitis C

  1997cited by this paper
• Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

  1997cited by this paper
• Incidence of dysthyroidism during interferon therapy in chronic hepatitis C.

  1997cited by this paper
• Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy

  1997cited by this paper
• Therapy of hepatitis C: Meta‐analysis of interferon alfa‐2b trials

  1997cited by this paper
• Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature.

  1997influential reference
• Side effects of high-dose interferon therapy for chronic hepatitis C.

  1996cited by this paper
• Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha.

  1996cited by this paper
• Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon‐α therapy

  1996cited by this paper
• Clinical associations between thyroid and liver diseases

  1995cited by this paper
• Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.

  1995cited by this paper
• Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association.

  1995cited by this paper
• Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis.

  1995cited by this paper
• Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction.

  1995cited by this paper
• Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.

  1995cited by this paper
• Prediction of interferon‐alpha‐induced thyroid dysfunction in patients with chronic hepatitis C

  1995cited by this paper
• Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon

  1994cited by this paper
• The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C.

  1994cited by this paper
• Exacerbation of Thyroid Autoimmunity by Interferon α Treatment in Patients with Chronic Viral Hepatitis

  1994cited by this paper
• Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature.

  1994cited by this paper
• Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C

  1993cited by this paper
• Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.

  1993cited by this paper
• Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa.

  1992cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Narrative review of pediatric thyroiditis: Diagnosis and management.

  2025cites this paper
• Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha

  2023cites this paper
• A systematic review and meta-analysis of endocrine-related adverse events associated with interferon

  2022cites this paper
• Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence

  2021cites this paper
• Клинические рекомендации «Острые и хронические тиреоидиты (исключая аутоиммунный тиреоидит)»

  2021cites this paper
• The interplay between thyroid and liver: implications for clinical practice

  2020cites this paper
• Prevalence of Thyroid Function Abnormalities in Patients with Chronic Renal Failure under Regular Hemodialysis

  2020influential citation
• HCV Extrahepatic Manifestations

  2019cites this paper
• Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir‐treated HCV‐infected patients: A real‐world clinical experience

  2018cites this paper
• Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection

  2017cites this paper
• Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.

  2017cites this paper
• Manifestaciones extrahepáticas asociadas a la infección crónica por el virus de la hepatitis C

  2017cites this paper
• Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy

  2016influential citation
• Interferon-Alpha and Ribavirin-Induced Thyroid Dysfunction in Chronic Hepatitis C Egyptian Patients: Incidence and Association

  2016cites this paper
• Hypothyroidism In Hepatitis C Patients On Pegylated Interferon Therapy.

  2016cites this paper
• Escitalopram zur Prävention Interferon-alpha-induzierter Depressionen bei Patienten mit einer chronischen Hepatitis-C-Infektion

  2015cites this paper
• Disfunção tireoidiana e sua associação com anticorpos não órgão específico (NOSAs) em portadores de hepatite C Thyroid dysfunction and its association with non-organ-specific antibodies (NOSAs) in hepatitis C carriers

  2015cites this paper
• Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.

  2015cites this paper
• Conséquences hépatiques des endocrinopathies et retentissement endocrinologique de l’insuffisance hépatique

  2014cites this paper
• Course of Graves Disease in Interferon-Treated Patients With Chronic Hepatitis C Virus Infection and in Uninfected Patients

  2013cites this paper
• Patterns of Interferon-Alpha–Induced Thyroid Dysfunction Vary with Ethnicity, Sex, Smoking Status, and Pretreatment Thyrotropin in an International Cohort of Patients Treated for Hepatitis C

  2013cites this paper
• Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction

  2013cites this paper
• Thyroid Dysfunctions and its Monitoring

  2013cites this paper
• Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis

  2013cites this paper
• Thyroid Dysfunction and Autoimmunity Among Patients with Chronic Hepatitis C Receiving Interferon-α Therapy

  2013cites this paper
• Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective.

  2013cites this paper
• The Place of Immunotherapy in the Management of HCV-Induced Vasculitis: An Update

  2012cites this paper
• [Thyroid and hepatitis C].

  2012cites this paper
• Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.

  2012cites this paper
• Thyroid Dysfunction in Chinese Patients with Chronic Hepatitis C Treated with Interferon Alpha: Incidence, Long-Term Outcome and Predictive Factors

  2012cites this paper
• Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection

  2012cites this paper
• SIDE EFFECTS PROFILE OF THERAPY FOR CHRONIC HEPATITIS C AND THEIR MANAGEMENT

  2012cites this paper
• Does Hepatitis C Virus Infection is a Relevant Factor for Thyroid Dysfunction ?

  2012cites this paper
• Organ-Specific Autoimmunity in HCV-Positive Patients

  2012cites this paper
• Association of Interferon-Alpha and Ribavirin-Induced Thyroid Dysfunction with Severity of Disease and Response to Treatment in Pakistani Asian Patients of Chronic Hepatitis C

  2012cites this paper
• con interferón-alfa para determinar el riesgo de tiroiditis autoinmune

  2011cites this paper
• HLA Status and Antithyroid Autoantibodies in Egyptian Patients with Chronic Hepatitis C Virus Infection

  2011cites this paper
• Citokine-induced thyroid disorders

  2011cites this paper
• Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C.

  2011cites this paper
• A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis.

  2011cites this paper
• A Case of Interferon Induced Hypothyroidism.

  2011cites this paper
• Seguridad de la terapia de interferón alfa 2b recombinante más ribavirina en la hepatitis crónica C

  2011cites this paper
• Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy.

  2011cites this paper
• Hypothyroidism in Noninterferon Treated-HCV Infected Individuals Is Associated with Abnormalities in the Regulation of Th17 Cells

  2010cites this paper
• Histopathologic findings of autoimmunity in thyroid, pituitary, and adrenal diseases in chronic hepatitis C postmortem cases.

  2010cites this paper
• Thyroid dysfunction in a UK hepatitis C population treated with interferon‐α and ribavirin combination therapy

  2010cites this paper
• Histopathological Findings of Autoimmunity in Thyroid , Pituitary and Adrenal Diseases in Chronic Hepatitis C Post-Mortem Cases

  2010cites this paper
• Interferon-Alpha Induced and Ribavirin Induced Thyroid Dysfunction in Patients with Chronic Hepatitis C

  2010cites this paper
• Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.

  2009cites this paper
• Thyroid dysfunction in patients with chronic hepatitis C: Virus‐ or therapy‐related?

  2009cites this paper
• Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection.

  2008cites this paper
• Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis.

  2008cites this paper
• Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.

  2008cites this paper
• Do Thyroid Abnormalities Detected in Patients Treated for HCV-Related Chronic Hepatitis Persist?

  2008cites this paper
• Treatment of chronic hepatitis C virus infection - Dutch national guidelines.

  2008cites this paper
• Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review.

  2008cites this paper
• Graves' ophthalmopathy and tongue cancer complicated by peg-interferon α-2b and ribavirin therapy for chronic hepatitis C: A case report and review of the literature.

  2008cites this paper
• Chapter 16 Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection

  2008cites this paper
• Safety of peginterferon in the treatment of chronic hepatitis C

  2008cites this paper
• Extrahepatic manifestations in patients with chronic hepatitis C virus infection.

  2008cites this paper
• Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha

  2007cites this paper
• Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

  2007cites this paper
• Granulomatous adenohypophysitis after interferon and ribavirin therapy.

  2007cites this paper
• Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations

  2007cites this paper
• [Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction].

  2007cites this paper
• Hepatitis C Infection, Treatment Regimens, and Thyroid Function Abnormalities

  2007cites this paper
• Sexual Dysfunction is Highly Prevalent Among Men with Chronic Hepatitis C Virus Infection and Negatively Impacts Health-Related Quality of Life

  2006cites this paper
• Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.

  2006cites this paper
• Treatment options for chronic hepatitis B and C infection in children

  2006cites this paper
• Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study.

  2006cites this paper
• The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon‐alpha and ribavirin combination therapy

  2006cites this paper
• Extrahepatic manifestations in patients with chronic hepatitis C virus infection

  2005cites this paper
• The uncertain natural history of thyrotoxic patients treated with combination interferon alfa-2beta and ribavirin.

  2005cites this paper
• Hipotiroidismo subclínico: Actualización

  2005cites this paper